Clinical

Latest News


Latest Videos


CME Content


More News

5 experts in this video

Panelists discuss how oral azacitidine plus venetoclax represents a transformative advance toward completely oral regimens that could dramatically improve quality of life and accessibility, though challenges remain regarding cost, insurance coverage, and the complexity of managing multiple oral agents.

5 experts in this video

Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with the greatest potential for novel agents likely in frontline combination settings.